Med-psych drug-drug interactions update

Psychosomatics

Volumn 43, Issue 1, 2002, Pages 77-81

  Armstrong, Scott C ^a   Cozza, Kelly L ^a   Oesterheld, Jessica R ^b  

^a Tuality Forest Grove Hospital   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; GLUCURONOSYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

ARTICLE; DRUG INTERACTION; HUMAN; PSYCHIATRY;

ANTICHOLESTEREMIC AGENTS; CHOLINESTERASE INHIBITORS; DRUG INTERACTIONS; GLUCURONOSYLTRANSFERASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PSYCHIATRY;

EID: 0036369869     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.psy.43.1.77     Document Type: Article

References (17)

1. O. Barbier D. Turgeon C. Girard 3′-azido-3′-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7) Drug Metab Dispos 28 2000 497 502
2. L. Iyer D. Hall S. Das Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism Clin Pharmacol Ther 65 1999 576 582
3. C.D. King G.R. Rios M.D. Green UDP-glucuronosyltransferases Curr Drug Metabol 1 2000 143 161
4. H.L. Liston J.S. Markowitz C.L. De Vane Drug glucuronidation in clinical psychopharmacology J Clin Psychopharmacol 21 2001 500 515
5. R.H. Tukey C.P. Strassburg Human UDP-glucuronosyltransferases: metabolism, expression, and disease Annu Rev Pharmacol Toxicol 40 2001 581 616
6. Eisai, Inc.: Aricept (donepezil hydrochloride) tablets (package insert). Teaneck, NJ, Eisai, Inc., December, 2000.
7. Parke Davis Pharmaceuticals, Ltd.: Cognex (tacrine hydrochloride) capsules (package insert). Morris Plains, NJ, Parke Davis Pharmaceuticals, Ltd., April, 2000.
8. Novartis Pharmaceuticals Corporation: Exelon (rivastigmine tartrate) capsules (package insert). East Hanover, NJ, Novartis Pharmaceuticals Corporation, January, 2001.
9. G.T. Grossberg H.B. Stahelin J.C. Messina Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications Int J Geriatr Psychiatry 15 2000 242 247
10. A. Nordberg A.L. Svensson Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology Drug Saf 19 1998 465 480
11. Janssen Pharmaceutica: Reminyl (galantamine hydrobromide) tablets (package insert). Titusville, NJ, Janssen Pharmaceutica Products, L.P., March, 2001.
12. E.G. Zurad New treatments of Alzheimer's disease: a review Behavioral Health Trends 13 2001 27 40
13. R.H. Boger Drug interactions of the statins and consequences for drug selection Int J Clin Pharmacol Ther 39 2001 369 382
14. K.L. Cozza S.C. Armstrong Internal medicine in Concise Guide to the Cytochrome P450 System 2001 American Psychiatric Publishing Inc Washington DC 128–129
15. T. Hatanaka Clinical pharmacokinetics of pravastatin Clin Pharmacokinet 39 2000 397 412
16. FDA Talk Paper: Bayer voluntarily withdraws Baycol. T01–34, August 8, 2001.
17. C.D. Scripture J.A. Pieper Clinical pharmacokinetics of fluvastatin Clin Pharmacokinet 40 2001 263 281